Transgenic microalgae as a non-antibiotic bactericide producer to defend against bacterial pathogen infection in the fish digestive tract.
Antibiotics are commonly employed in most fish aquacultures to prevent disease. One major risk in this practice is that antibiotic-resistant pathogens may be selected. Therefore, we wanted to examine the feasibility of producing an economical, non-antibiotic alternative. The microalga Nannochloropsis oculata is an essential phytoplankton used as live feed for fish larvae. We attempted to culture N. oculata in a way that would provide an organism against bacterial pathogenic infection. To test this idea, we constructed an algae-codon-optimized bovine lactoferricin (LFB) fused with a red fluorescent protein (DsRed) driven by a heat-inducible promoter, which is a heat shock protein 70A promoter combined with a ribulose-1,5-bisphosphate carboxylase/oxygenase small subunit 2' promoter from Chlamydomonas reinhardtii. After electroporation, we examined 491 microalgal clones and generated two stable transgenic lines, each expressing a stable transgene inheritance for at least 26 months. This was confirmed by the positive detection of the mRNA transcript and the protein of LFB-DsRed produced by the transgenic microalgae. To test the efficacy of the antimicrobial peptide LFB, medaka fish (Oryzias latipes) were adapted from freshwater to seawater and were fed with the transgenic algae by oral-in-tube delivery method. Bacterial infection with 1 x 10(5)Vibrio parahaemolyticus per fish was induced 6h thereafter by oral-in-tube delivery as well. For medaka fish fed with 1 x 10(8) transgenic algae per fish, the average survival rate after a 24-h period of infection was much higher than that of medaka fed with wild-type algae (85+/-7.1% versus 5+/-7.1%). This result suggests that medaka fish fed with the LFB-containing transgenic microalgae will have bactericidal defense against V. parahaemolyticus infection in its digestive tract.
Li
Si-Shen
SS
Institute of Molecular and Cellular Biology, National Taiwan University, No. 1, Section 4, Roosevelt Road, Taipei 106, Taiwan.
Tsai
Huai-Jen
HJ
D020418:Algal Proteins / Q000032:analysis / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D056890:Eukaryota / Q000235:genetics* / Q000378:metabolism*; D005393:Fish Diseases / Q000628:therapy*; D041981:Gastrointestinal Tract / Q000382:microbiology*; D007781:Lactoferrin / Q000235:genetics / Q000494:pharmacology; D030781:Organisms, Genetically Modified; D009990:Oryzias / Q000382:microbiology / Q000502:physiology*; D010957:Plasmids / Q000235:genetics; D011523:Protoplasts / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D016019:Survival Analysis; D014735:Vibrio Infections / Q000628:therapy / Q000662:veterinary*; D014736:Vibrio parahaemolyticus / Q000502:physiology
D020418:Algal Proteins; D011994:Recombinant Proteins; C082171:lactoferricin B; D007781:Lactoferrin